Tag Archives: TOWER study

February, 2016

  • 5 February

    Amgen’s Blincyto Meets Primary Endpoint in Late-Stage ALL Study

    THOUSAND OAKS, Calif., Feb. 4, 2016 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the results of a prespecified interim analysis showed that the primary endpoint of improved overall survival was met in the Phase 3 TOWER study. The randomized, open-label TOWER study evaluated the efficacy of BLINCYTO® (blinatumomab) versus standard of care …